Please assess the completion status of the following clinical trial:

Trial Title: BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to the ICU with severe pneumonia (IDSA/ATS 2016/2019): presence of signs, symptoms and confirmatory chest imaging consistent with pneumonia (e.g. fever, cough and pulmonary infiltrate by chest radiograph)~* Age ≥18 years~* Positive respiratory culture (with or without an initial positive rapid identification test and/or Gram stain) for Gram-negative bacteria including, but not limited to, P. aeruginosa, K. pneumoniae, E. coli, S. marcescens, H. influenzae, Enterobacter spp., M. catarrhalis, A. baumannii, Achromobacter spp., P. mirabilis, and/or B. cepacia~* Received within the last 72 hours or will receive meropenem, cefepime, or piperacillin/tazobactam therapy~Exclusion Criteria:~* Pregnancy~* Prisoners~* Allergy to the beta-lactams to be administered in this study~* On renal replacement therapy at the time of randomization~* Baseline culture resistant to the beta-lactams in the study~* COVID patients enrolled in other trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Continuous Antibiotic Dose Over 24 hours Arm (Type: ACTIVE_COMPARATOR): Subjects will be receiving a continuous dose of antibiotic prescribed by their doctor for the duration they choose.
- Intermittent Antibiotic Dose Over 30 minutes (Type: ACTIVE_COMPARATOR): Subjects will be receiving an intermittent dose of antibiotic prescribed by their doctor for the duration they choose.

Based on this trial design, predict the completion outcome and termination type (if applicable).